A phase II, multicenter, open-label study of polyPEPI1018 in combination with atezolizumab in participants with relapsed or refractory microsatellite-stable metastatic colorectal (MSS mCRC) cancer (Oberto-301).

被引：0
|
作者：
Hubbard, Joleen M.
Ahn, Daniel H.
Jones, Jeremy Clifton
Zhu, Mojun
Wittenberger, Kathleen
Csiszovszki, Zsolt
Somogyi, Eszter
Lorincz, Orsolya
Molnar, Levente
Toth, Jozsef
Youssoufian, Hagop
Toke, Eniko Rita
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Mayo Clin, Div Med Oncol, Phoenix, AZ USA
[3] Mayo Clin Florida, Jacksonville, FL USA
[4] Mayo Clin Rochester, Dept Med Oncol, Rochester, MN USA
[5] TreosBio, Veszprem, Hungary
[6] Treos Bio, Veszprem, Hungary
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3594
引用
收藏
页数：1
相关论文
共 50 条
  • [21] CXD101 and nivolumab in patients with metastatic microsatellite-stable colorectal cancer (CAROSELL): a multicentre, open-label, single-arm, phase II trial
    Saunders, M. P.
    Graham, J.
    Cunningham, D.
    Plummer, R.
    Church, D.
    Kerr, R.
    Cook, S.
    Zheng, S.
    La Thangue, N.
    Kerr, D.
    ESMO OPEN, 2022, 7 (06)
  • [22] Phase II study of pembrolizumab plus capecitabine and bevacizumab in microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Interim analysis.
    Bocobo, Andrea Grace
    Wang, Renee
    Behr, Spencer
    Carnevale, Julia C.
    Cinar, Pelin
    Collisson, Eric Andrew
    Fong, Lawrence
    Kidder, Wesley Allen
    Ko, Andrew H.
    Kolli, Kanti Pallav
    Kennedy, Megan
    Laffan, Angela
    Lindsay, Sheila
    Nalla, Sneha
    Schwartz, Gabriel
    Whitman, Julia
    Zendejas, Patricia
    Zhang Li
    Van Loon, Katherine
    Atreya, Chloe Evelyn
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [23] Interim analysis of the phase II AVETUXIRI trial: Avelumab combined with cetuximab and irinotecan for treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
    Huyghe, Nicolas
    De Cuyper, Astrid
    Sinapi, Isabelle
    Vempalli, Fazulur Rehaman
    Rinchai, Darawan
    Beyaert, Simon
    Verstraelen, Eleonore
    Goffette, Pierre
    Ghaye, Benoit
    Gilet, Melanie
    Van Maanen, Aline
    Castella, Marie-Laure
    Mlecnik, Bernhard
    Carrasco, Javier
    Galon, Jerome
    Bedognetti, Davide
    Van den Eynde, Marc
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [24] Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study
    Elez, Elena
    Cubillo, Antonio
    Alfonso, Pilar Garcia
    Middleton, Mark R.
    Chau, Ian
    Alkuzweny, Baha
    Alcasid, Ann
    Zhang, Xiaosong
    Van Cutsem, Eric
    BMC CANCER, 2024, 24 (01)
  • [25] STOPTRAFFIC-1: A phase I/II trial of SX-682 in combination with nivolumab for refractory RAS-mutated microsatellite stable (MSS) metastatic colorectal cancer (mCRC)
    Johnson, Benny
    Kopetz, Scott
    Hwang, Hyunsoo
    Yuan, Ying
    DePinho, Ronald Anthony
    Zebala, John
    Overman, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [26] Phase II study of durvalumab anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)
    Johnson, Benny
    Haymaker, Cara L.
    Parra, Edwin R.
    Soto, Luisa Maren Solis
    Wang, Xuemei
    Thomas, Jane, V
    Dasari, Arvind
    Morris, Van K.
    Raghav, Kanwal
    Vilar, Eduardo
    Kee, Bryan K.
    Eng, Cathy
    Parseghian, Christine M.
    Wolff, Robert A.
    Lee, Younghee
    Lorenzini, Daniele
    Laberiano-Fernandez, Caddie
    Verma, Anuj
    Lang, Wenhua
    Wistuba, Ignacio I.
    Futreal, Andrew
    Kopetz, Scott
    Overman, Michael J.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (08)
  • [27] Phase II study of combination ipilimumab, nivolumab, and panitumumab in patients with KRAS, NRAS, and BRAF wild-type (WT) microsatellite stable (MSS) metastatic colorectal cancer (mCRC)
    Lee, Michael
    Loehrer, Patrick
    Imanirad, Iman
    Cohen, Stacey
    Ciombor, Kristen
    Carlson, Cheryl
    Sanoff, Hanna
    McRee, Autumn
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [28] Avelumab (AVE), cetuximab (CET) and irinotecan (IRI) for treatment refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Translational analyses of the AVETUXIRI phase II trial
    Huyghe, N.
    Benidovskaya, E.
    Masoodi, T.
    Carrasco, J.
    De Cuyper, A.
    Sinapi, I.
    Vempalli, F.
    Verstraelen, E.
    Goffette, P.
    Ghaye, B.
    Papier, M.
    Bedognetti, D.
    van Maanen, A.
    Castella, M-L.
    Galon, J.
    van den Eynde, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S1152 - S1152
  • [29] A phase II study of durvalumab (MEDI4736) (anti-PDL1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)
    Johnson, Benny
    Thomas, Jane V.
    Dasari, Arvind
    Raghav, Kanwal Pratap Singh
    Sanchez, Eduardo Vilar
    Kee, Bryan K.
    Eng, Cathy
    Parseghian, Christine Megerdichian
    Morris, Van K.
    Wolff, Robert A.
    Shureiqi, Imad
    Kopetz, Scott
    Overman, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [30] Fruquintinib plus sintilimab in refractory repair-proficient (pMMR)/microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Preliminary clinical results and biomarker analyses from a phase II study
    Zhang, W.
    Sun, Y.
    Jiang, Z.
    Liu, T.
    Gong, C.
    Yang, L.
    Xin, Y.
    Huang, D.
    Zhou, A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S728 - S728
12345